Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity.

CONCLUSIONS: We propose that PD-L2 as well as PD-L1 play important roles in evading antitumor immunity, suggesting that PD-1/PD-L2 blockade must be considered for optimal immunotherapy in PD-L2-expressing cancers, such as RCC and LUSC.
PMID: 31076547 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 9, 2019 Category: Cancer & Oncology Authors: Nishikawa H, Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M Tags: Clin Cancer Res Source Type: research